Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
Randa Bascharon, Founder, President and Orthopedic Surgeon at Sports Performance Institute of Las Vegas, shared a post on LinkedIn:
“Wharton’s Jelly is increasingly discussed in orthopedic and sports medicine settings, particularly among active patients looking for non-surgical options.
Wharton’s Jelly is derived from donated umbilical cord tissue and contains growth factors and signaling proteins that may support the body’s healing environment.
In clinical practice, it is considered in select cases involving tendon injuries, ligament issues, or certain joint conditions.
A few practical points are important:
- First, it is not the same as a steroid injection.
- Second, it is different from platelet-rich plasma.
- Third, it is not a universal substitute for surgery.
Candidacy varies.
The decision to consider a biologic injection depends on the diagnosis, severity of tissue damage, functional goals, prior treatments, and imaging findings.
Thoughtful patient selection matters.
For athletes and active adults, the real question is not whether a treatment is popular.
It is whether it aligns with the biology of their specific injury and their long-term performance goals.
If you are seeing more patients ask about biologics, how are you approaching education and expectation setting in your practice?
Educational only.
A diagnosis and treatment plan require an in-person evaluation.”
See more in the gallery.
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 18:45Elias Lee: Acute PE from Subclavian VT – CT Scan Diagnosis, Radiology Interpretation, and Emergency Imaging Insights
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 16:53Sickle Cell Disease Care Varies by Region – ASH
-
Apr 15, 2026, 16:40Jorge Lima։ Understanding Recurrent Pregnancy Loss
-
Apr 15, 2026, 16:26Pregnancy-Induced Rise in FIX Activity – A Challenge to International Hemophilia Guidelines – JTH
-
Apr 15, 2026, 16:18Ken Checicki: How Restoring Blood Flow Can Solve Post – DVT Complications